


Ifw

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the US Postal Service with sufficient postage as First Class Mail in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below.

Date: July 12, 2007

By: *Aida Martin*
Aida Martin



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)	Group Art Unit:
)	
Grant, et al.)	Examiner:
)	
Serial No.: 10/549,603)	
)	
Filed: April 28, 2004)	
)	
For: Novel Bacillus MHKcel Celluase)	
)	

TRANSMITTAL LETTER

Commissioner for Patents
P.O Box 1450
Alexandria, VA 22313-1450

Sir:

Enclosed please find the following documents: Information Disclosure Statement, Form 1449, and the cited references for the above-identified patent application.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16 and 1.17 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 07-1048 (Docket No. GC797-2-US). A duplicate of this paper is enclosed.

Respectfully submitted,

Date: July 12, 2007

Victoria L. Boyd
Victoria L. Boyd
Registration No. 43,510

Genencor International, Inc.
925 Page Mill Road
Palo Alto, CA 94304-1013
Tel: 650-846-7615
Fax: 650-845-6504



CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the US Postal Service with sufficient postage as First Class Mail in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below.

Date: July 12, 2007

By: _____

Aida Martin

Aida Martin

PATENT

Attorney Docket No. GC797-2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)	Group Art Unit:
)	
Grant, et al.)	Examiner:
)	
Serial No.: 10/549,603)	
)	
Filed: April 28, 2004)	
)	
For: Novel Bacillus mHKcel Cellulase)	
)	
)	
)	
)	
)	

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants submit herewith patents, publications or other information (listed on the attached Form PTO-1449 and attached thereto) of which they are aware, that they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement:

(a) ☐ accompanies the new patent application submitted herewith. 37 CFR §1.97(a).

GC797-2-US IDS

(b) ☐ is filed within three months after the filing date of the application or within three months after the date of entry into the national stage of a PCT application as set forth in 37 CFR §1.491.

(c) ☒ as far as is known to the undersigned, is filed before the mailing date of a first Office Action on the merits.

(d) ☐ is filed after the first Office Action and more than three months after the application filing date or PCT national stage date of entry filing but, as far as is known to the undersigned, prior to the mailing date of either a final rejection or a notice of allowance, whichever occurs first, and is accompanied by either the fee (\$180.00) set forth in 37 CFR §1.17(p) or a certification as specified in 37 CFR §1.97(e), as checked below. Authorization to charge Deposit Account No. 07-1048 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement is provided in the Transmittal Letter submitted herewith in duplicate.

(e) ☐ is filed after the mailing date of either a final rejection or a notice of allowance, whichever occurred first, and is accompanied by authorization (in the Transmittal Letter submitted herewith in duplicate) to charge Deposit Account No. 07-1048 the fee (\$180.00) set forth in 37 CFR §1.17(l)(1) and a certification as specified in 37 CFR §1.97(e), as checked below. **This document is to be considered as a petition requesting consideration of the Supplemental Information Disclosure Statement.**

[If either of boxes (d) or (e) is checked above, the following "certification" under 37 CFR §1.97(e) must be completed.] The undersigned certifies that:

☐ Each item of information contained in the Information Disclosure Statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

☐ No item of information contained in this Information Disclosure Statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application and to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

A copy of the items on Form PTO-1449 is supplied: PCT International Search Report for, mailed_____, with attached patents and publications.

☒ each ☐ none ☐ only those listed below:

Serial No. 10/549,603
Filed: April 28, 2004

Those patent(s) or publication(s) which are marked with an asterisk (*) on the attached Form PTO-1449 are not supplied because they were previously cited by or submitted to the Office in a prior application, Serial No. _____ filed _____, and relied upon in this application for an earlier filing date under 35 USC 120.

Those patent(s) or publication(s) which are marked with an asterisk (**) on the attached Form PTO-1449 (**Books not sent**) are not supplied. Complete bibliographic information is unknown or unavailable. The cited publications are books or reference manuals and are commonly available. Reproduction of such publications would result in a voluminous submission.

A concise explanation of relevance of the items listed on PTO-1449 is:

- ☒ not given
- ☐ given for each listed item
- ☐ given for only non-English language listed item(s)
- ☐ in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

The Examiner is reminded that a "concise explanation of the relevance" of the submitted prior art "may be nothing more than identification of the particular figure or paragraph of the patent or publication which has some relation to the claimed invention." MPEP §609.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR §1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.


In accordance with 37 CFR §1.97(b), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as

Serial No. 10/549,603
Filed: April 28, 2004

defined in 37 CFR §1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR §1.98 and MPEP §609 and the Examiner is respectfully requested to consider the listed references.

Respectfully submitted,

Dated: July 12, 2007


Victoria L. Boyd
Reg. No. 43,510

Genencor International, Inc.
925 Page Mill Road
Palo Alto, CA 94304-1013
Tel.: (650) 846-7615
Fax: (650) 845-6504

INFORMATION DISCLOSURE CITATION

Attorney Docket No.: GC797-2	Serial No.: 10/549,603
Applicant: Grant, et al.	
Filing Date: April 28, 2004	Group:
Page <u>1</u> of <u>2</u>	Date of this Submission: July 12, 2007

US PATENT DOCUMENTS


Examiner's	Document				Sub-	Filing
Initial	Number	Date	Name	Class	Class	Date
	4,338,397	7-6-82	Gilbert et al.			
	4,411,994	10-25-83	Gilbert et al.			
	4,513,085	4-23-85	Nakatsukasa, et al.			
	4,513,086	4-23-85	Fryerman, et al.			
	4,738,682	4-19-88	Boegh, et al.			
	4,745,056	5-17-88	Guterman, et al.			
	5,254,283	10-19-93	Arnold, et al.			
	5,264,366	11-23-93	Ferrari, et al.			
	5,364,770	11-15-94	Berka, et al.			
	5,514,590	5-17-96	Garvin, et al.			
	5,622,866	4-22-97	Motamedi, et al.			
	6,255,115	7-3-01	Beijersbergen, et al.			

FOREIGN PATENT DOCUMENTS

Examiner's	Document				Sub-	Translation
Initials	Number	Date	Country	Class	Class	Yes/No
	684,304		EPO			
	87 372		Finland			
	1,368,599		GB			
	2 094 826 A		GB			
	2,095,275.		GB			
	220 016		EPO			
	WO88/07079		PCT			
	WO95/16360		PCT			

OTHER DOCUMENTS

Examiner's	Author, Title, Date, Pertinent Pages, etc.
Initials	
	Bajar, Podila and Kolattukudy (1991), Proc. Natl. Acad. Sci. USA 88: 8202-8212. <i>Identification of a fungal cutinase promoter that is inducible by a plant signal via a phosphorylated trans-acting factor.</i>
	Brigidi, DeRossi, Bertarini, Riccardi and Matteuzzi, 1990, FEMS Microbiol. Lett. 55: 135-138. <i>Genetic transformation of intact cells of Bacillus subtilis by electroporation.</i>
	Evan et al., Molecular and Cellular Biology 5:3610-3616 (1985). <i>Isolation of Monoclonal</i>



	Antibodies Specific for Humans c-myc Proto-Oncogene Product.
	Field et al., Mol. Cell. Biol. 8:2159-2165 (1988). Purification of a RAS-Responsive Adenylyl Cyclase Complex From <i>Saccharomyces cerevisiae</i> .
	Gilman and Smith, Gene 8:81-97 (1979). Site-Specific Mutagenesis Using Synthetic Oligodeoxyribonucleotide Primers:
	Goldman, VanMontagu and Herrera-Estrella, 1990, Curr. Genet. 17:169-174. Transformation of <i>Trichoderma Harizanum</i> by High-voltage electric pulse.
	Hopp et al., BioTechnology 6:1204-1210 (1988). A Short Polypeptide Marker Sequence Useful For Recombinant Protein Identification and Purificatio.
	Lomovskaya et al., J. Virology 9:258 (1972). Characterization Of Temperate Actinophage C31 Isolated from <i>Streptomyces coelicolor</i> A3(2).
	Lorito, Hayes, DiPietro and Harman, 1993, Curr. Genet. 24: 349-356; Biolistic Transformation Of <i>Trichoderma Harzianum</i> and <i>Gliocladium virens</i> using plasmid and geomic DNA.
	Lutz-Freyermuth et al., Proc. Natl. Acad. Sci. USA 87:6393-6397 (1990). Quantitative Determination that one of two potential RNA-binding domains of the A protein component of the U1 small nuclear ribonucleoprotein complex binds with high affinity to stem-loop II of U1 RNA.
	Martin et al., Science 255:192-194 (1992); Gap Domains Responsible for Ras p21-Dependent Inhibition of Muscarinic Atrial K ⁺ Channel Currents.
	Paborsky et al., Protein Engineering 3(6):547-553 (1990). Mammalian Cell Transient Expression of Tissue Factor For the production of antigen
	Penttila, Nevalainen, Ratto, Salminen and Knowles, 1987, Gene 6: 155-164. A Versatile Transformation System for the Cellulolytic Filamentous Fungus <i>Trichoderma reesei</i> .
	R. Teather and P.J. Wood, Applied & Environmental Microbiology, 43: 770-780 (1982). Use of Congo Red-Polysaccharide Interactions in Enumeration and Characterization of Cellulolytic Bacteria from the Bovine Rumen.
	Roberts et al., Nature 328:731-734 (1987). Generation of an antibody with enhanced affinity and specificity for its antigen by protein engineering.
	Scheider, B., et al., Protein Expr. Purif 6:435-10 (1995). Functional Purification of a Bacterial ATP-Binding Cassette Transporter Protein (MalK) from the Cytoplasmic Fraction of an Overproducing Strain.
	Shoemaker S.P. and Brown R.D.Jr. (Biochim. Biophys. Acta, 1978, 523:133-146) Enzymic Activited of Endo-1, 4B-D Glucanases Purified From <i>Trichoderma Viride</i> .
	Skinner et al., J. Biol. Chem. 266:15163-15166 (1991). Use of the Glu0Glu-Phe C- Terminal Epitope for Rapid Purification of the Catalytic Domain of Normal and Mutant ras GTPase-activating Proteins.
	Yelton, Hamer and Timberlake, 1984, Proc. Natl. Acad. Sci. USA 81: 1470-1474. Tranformation of <i>Aspergillus nidulans</i> by using a trpC plasmid.

Examiner	Date Considered
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not	
considered. Include copy of this form with next communication to applicant.	
PTO-1449	